Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Zolpidem 10 mg Clear all
Recruiting Phase 4 Interventional

The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

NCT05746143
View directory record Official record
Conditions
Spine Fusion, Lumbar Spine Degeneration, Pain, Postoperative, Lumbar Spine Spondylosis
Interventions
Zolpidem Tartrate 10 mg, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Results available

Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia

NCT03774810
View directory record Official record
Conditions
Insomnia, Insomnia Chronic
Interventions
Zolpidem tartrate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions

NCT00779441
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2008 · Synced Oct 2, 2026, 1:35 PM EDT
Recruiting Phase 4 Interventional

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

NCT07542756
View directory record Official record
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Early Phase 1 Interventional

Proton MRS Study of SSRI-Zolpidem Interactions

NCT01809626
View directory record Official record
Conditions
Depression
Interventions
Zolpidem, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep

NCT01485393
View directory record Official record
Conditions
Insomnia
Interventions
Dexmedetomidine, Zolpidem
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 2, 2026, 1:35 PM EDT
Withdrawn Phase 2 Interventional

Use of Zolpidem in Parkinson's Disease

NCT01351168
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

NCT00716521
View directory record Official record
Conditions
Methodology Study
Interventions
placebo, zolpidem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2009 · Synced Oct 2, 2026, 1:35 PM EDT
Terminated Not applicable Interventional Results available

Sleep and Endometrial Cancer

NCT00936598
View directory record Official record
Conditions
Sleep, Endometrial Neoplasms, Pain
Interventions
zolpidem, sugar pill
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypnotic Medications and Memory: Effect of Drug Exposure During the Night

NCT01159652
View directory record Official record
Conditions
Sleep, Memory
Interventions
zaleplon, zolpidem extended release, bedtime placebo, middle of the night placebo
Drug
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

NCT00833521
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
LY2624803, Placebo, zolpidem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 2, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

NCT04009577
View directory record Official record
Conditions
Insomnia
Interventions
LEM 5 mg, LEM 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Glendale, Arizona • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 2, 2026, 1:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 2, 2026, 1:35 PM EDT
Recruiting Phase 2 Interventional

Trial of Zolpidem for Sleep in Children With Autism

NCT05540574
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 2, 2026, 1:35 PM EDT